PRECISION RADIOTHERAPEUTICS
AND ONCOLOGY PROGRAMME
About Us
Our passion and goal is to develop highly personalized forms of clinical treatment for nasopharyngeal, prostate, head and neck cancer. As every tumor has it's own unique characteristics, understanding these characteristics could help us predict the success rate of today's therapies. Utilizing bioinformatics enable us to analyze datasets, which are used to create clinical diagnostic tools for personalized therapy.
This laboratory is led by Prof Soo Khee Chee and Dr. Melvin Chua, together with individuals from a variety of research backgrounds and qualifications. This diversity brings in different talents together, all of us working towards a common goal using different skill sets.
Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma
Platinum-based concurrent chemoradiotherapy is the standard of care for patients with locoregionally advanced nasopharyngeal carcinoma. Additional gemcitabine and cisplatin induction chemotherapy has shown promising efficacy in phase 2 trials.
Chemotherapy in Combination With Radiotherapy for Definitive-Intent Treatment of Stage II-IVA Nasopharyngeal Carcinoma: CSCO and ASCO Guideline
This joint guideline aims to provide evidence-based recommendations to practicing physicians and other healthcare providers on definitive-intent chemoradiotherapy for patients with stage II-IVA nasopharyngeal carcinoma (NPC).
Efficacy and Safety of Locoregional Radiotherapy With Chemotherapy vs Chemotherapy Alone in De Novo Metastatic Nasopharyngeal Carcinoma: A Multicenter Phase 3 Randomized Clinical Trial
The role of locoregional radiotherapy in patients with de novo metastatic nasopharyngeal carcinoma is unclear. This randomized clinical trial examines the efficacy and safety of locoregional radiotherapy vs raditherapy alone in patients with de novo metastatic nasopharyngeal carcinoma.
